Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.

Gorden P, Park JY.

Arch Physiol Biochem. 2006 Apr;112(2):114-8. Review.

PMID:
16931453
2.

The clinical uses of leptin.

Gorden P, Gavrilova O.

Curr Opin Pharmacol. 2003 Dec;3(6):655-9. Review.

PMID:
14644019
3.

Rethinking leptin and insulin action: therapeutic opportunities for diabetes.

Yildiz BO, Haznedaroglu IC.

Int J Biochem Cell Biol. 2006;38(5-6):820-30. Epub 2005 Oct 3. Review.

PMID:
16236542
4.

Leptin-replacement therapy for lipodystrophy.

Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A.

N Engl J Med. 2002 Feb 21;346(8):570-8.

5.

Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.

Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P.

Diabetes. 2005 Jul;54(7):1994-2002.

6.

Hypothalamic melanocortin signaling and leptin resistance--perspective of therapeutic application for obesity-diabetes syndrome.

Masuzaki H, Tanaka T, Ebihara K, Hosoda K, Nakao K.

Peptides. 2009 Jul;30(7):1383-6. doi: 10.1016/j.peptides.2009.04.008. Epub 2009 Apr 23. Review.

PMID:
19394382
7.

The clinical utility of leptin therapy in metabolic dysfunction.

Park JY, Gavrilova O, Gorden P.

Minerva Endocrinol. 2006 Jun;31(2):125-31. Review.

PMID:
16682936
8.

Health risks of lipodystrophy and abdominal fat accumulation: therapeutic possibilities with leptin and human growth hormone.

Van Gaal LF, Mertens IL, Abrams PJ.

Growth Horm IGF Res. 2003 Aug;13 Suppl A:S4-9. Review.

PMID:
12914718
9.

[Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].

Jazet IM, Jonker JT, Wijngaarden MA, Lamb H, Smelt AH.

Ned Tijdschr Geneeskd. 2013;157(4):A5482. Review. Dutch.

PMID:
23343738
10.

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI.

J Clin Invest. 2002 May;109(10):1345-50.

11.

Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin.

Miyamoto L, Ebihara K, Kusakabe T, Aotani D, Yamamoto-Kataoka S, Sakai T, Aizawa-Abe M, Yamamoto Y, Fujikura J, Hayashi T, Hosoda K, Nakao K.

J Biol Chem. 2012 Nov 23;287(48):40441-7. doi: 10.1074/jbc.M112.384545. Epub 2012 Sep 28.

12.

20 years of leptin: leptin in common obesity and associated disorders of metabolism.

DePaoli AM.

J Endocrinol. 2014 Oct;223(1):T71-81. doi: 10.1530/JOE-14-0258. Epub 2014 Jun 27. Review.

13.

The therapeutic potential of leptin.

Proietto J, Thorburn AW.

Expert Opin Investig Drugs. 2003 Mar;12(3):373-8. Review.

PMID:
12605561
14.

Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency.

McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA.

J Clin Endocrinol Metab. 2004 Sep;89(9):4258-63.

15.

Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin.

Gómez R, Lago F, Gómez-Reino JJ, Gualillo O.

Expert Opin Ther Targets. 2009 May;13(5):583-91. doi: 10.1517/14728220902914834 . Review.

PMID:
19397477
16.

Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.

Rodríguez AJ, Neeman T, Giles AG, Mastronardi CA, Paz Filho G.

Arq Bras Endocrinol Metabol. 2014 Nov;58(8):783-97. Epub 2014 Nov 1. Review.

17.

Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?

Machado MV, Cortez-Pinto H.

Expert Rev Gastroenterol Hepatol. 2013 Aug;7(6):513-5. doi: 10.1586/17474124.2013.814903.

PMID:
23985000
18.

Leptin and insulin resistance: good, bad, or still unclear?

Oral EA, Burant C.

Am J Physiol Endocrinol Metab. 2009 Feb;296(2):E394-5, author reply E396. doi: 10.1152/ajpendo.90914.2008. No abstract available.

19.

Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice.

Singhal NS, Patel RT, Qi Y, Lee YS, Ahima RS.

Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E331-8. doi: 10.1152/ajpendo.00577.2007. Epub 2008 May 27.

20.

Leptin in congenital and HIV-associated lipodystrophy.

Tsoukas MA, Farr OM, Mantzoros CS.

Metabolism. 2015 Jan;64(1):47-59. doi: 10.1016/j.metabol.2014.07.017. Epub 2014 Aug 12. Review.

PMID:
25267014

Supplemental Content

Support Center